DOCSLIB.ORG

Ep 1765376 B1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ep 1765376 B1 (19) TZZ_¥_T (11) EP 1 765 376 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/198 (2006.01) A61K 8/44 (2006.01) 10.04.2013 Bulletin 2013/15 A61K 8/46 (2006.01) A61K 8/49 (2006.01) A61K 9/00 (2006.01) A61Q 19/00 (2006.01) (21) Application number: 05757465.9 (86) International application number: (22) Date of filing: 13.06.2005 PCT/US2005/020555 (87) International publication number: WO 2005/123103 (29.12.2005 Gazette 2005/52) (54) Topical compositions and use thereof for the treatment of epithelial-related conditions Topische Zusammensetzungen und Verwendung davon zur Behandlung von epithelialbedingte Leiden Compositions topiques et utilisation de celles-ci pour lutter contre des maladies epitheliales (84) Designated Contracting States: (74) Representative: ABG Patentes, S.L. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Avenida de Burgos, 16D HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR Edificio Euromor 28036 Madrid (ES) (30) Priority: 12.06.2004 US 579093 P 14.02.2005 US 652921 P (56) References cited: WO-A-2004/087064 US-A- 5 043 268 (43) Date of publication of application: US-A- 5 202 456 US-A- 5 202 456 28.03.2007 Bulletin 2007/13 US-A- 5 705 528 (73) Proprietor: SIGNUM BIOSCIENCES, INC. • CLARKE ET AL: "Ras antagonist Monmouth Junction, NJ 08852 (US) farnesylthiosalicylic acid (FTS) reduces glomerularcellular proliferation and macrophage (72) Inventors: number in rat Thy- 1 nephritis" JOURNAL OF THE • STOCK, Jeffry B. AMERICAN SOCIETY OF NEPHROLOGY, vol. 14, Rocky Hill, NJ 08553 (US) 2003, pages 848-854, XP002518799 • GORDON, Joel • DING J ET AL: "FARNESYL-L-CYSTEINE Princeton Junction, NJ 08550 (US) ANALOGS CAN INHIBIT OR INITIATE • STOCK, Maxwell SUPEROXIDE RELEASE BY HUMAN Rocky Hill, NJ 08553 (US) NEUTROPHILS" JOURNAL OF BIOLOGICAL • STOCK, Gregory CHEMISTRY, AMERICAN SOCIETY OF Princeton, NJ 08542 (US) BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 269, no. 24, 17 June 1994 (1994-06-17), pages 16837-16844, XP001151963 ISSN: 0021-9258 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 765 376 B1 Printed by Jouve, 75001 PARIS (FR) 1 EP 1 765 376 B1 2 Description they interact, or other intracellular signaling proteins, can be used to mitigate leukocyte responses and, theoreti- CROSS REFERENCE TO RELATED APPLICATIONS cally, to treat inflammatory-related conditions. (see e. g. Volker et al., Methods Enzymol., 1995,250, 216-225). [0001] This application claims the benefit of priority of 5 WO 2004/087064 describes a method for the treatment U.S. Provisional Application No. 60/579,093 filed on June of neoplasia, including cancer and other diseases and 12, 2004. This application also claims the benefit of pri- conditions in humans and mammals. More particularly, ority of U.S. Provisional Patent Application No.it provides a method for the use of prenylcysteine analogs 60/652,921 filed on February 14, 2005. The entire dis- for the treatment of neoplasia, hyperproliferative cell closures of U.S. Provisional Patent Application No.10 growth including psoriasis, restenosis following cardio- 60/597,093 and U.S. Provisional Patent Application No. vascular surgery, hyperplasia, including renal hyperpla- 60/652,921 are herein incorporated by reference. sia, chronic inflammatory diseases including rheumatoid and osteoarthritis, among others. US5043268 describes FIELD OF THE INVENTION a specific class of compounds as substrates and/or in- 15 hibitors specifically for prenyl cysteine methyltransferase [0002] The present invention relates to pharmaceuti- enzymes which catalyze the methyl transfer from S-ad- cal, cosmetic and cosmeceutical topical compositions enosylmethionine to the C-termini of proteins and pep- containing polyisoprenyl-protein inhibitor compounds tides with prenylated cysteine residus at their C-termini. and methods useful in the promotion of healthy epitheli- The compounds, as substrates, are described as being um and the treatment of epithelial-related conditions. 20 particularly suitable for use in assays for qualitatively or quantitatively detecting the farnesyl cysteine methyl- BACKGROUND OF THE INVENTION transferase enzymes. [0006] One such compound is N-acetylfar- [0003] Many skin or mucosal membrane conditions or nesyl-cysteine (AFC). AFC has been shown to inhibit disorders result from inflammation caused by, inter alia 25 membrane-associated polyisoprenoid methyl trans- bacteria, fungi, viruses, parasites, autoimmune disor- ferase and to block some neutrophil, macrophage, and ders, allergens, environmental conditions, such as ex- platelet responses in vitro. Unfortunately, AFC requires treme temperatures, wounds, hormones and/or malig- high concentrations for efficacy and is expected to result nant agents. Thus, inflammation can be associated with in generalized systemic effects and multiple side effects numerous underlying conditions ranging from dry skin to 30 since it interferes with a central cell regulation mecha- infections to cancer, as well as being symptomatic of in- nism, characteristics which would seem to preclude its flammatory disorders such as dermatitis. use in vivo. However, because such inhibitory com- [0004] Inflammation is often characterized by a strong pounds have the potential to be highly efficacious, there infiltration of leukocytes at the site of inflammation, par- is a need in the art for compositions containing these ticularly neutrophils (polymorphonuclear cells). These 35 compounds that can act as a safe and effective antidote cells promote tissue damage by releasing toxic substanc- for skin and mucosal membrane conditions. es at the vascular wall or in uninjured tissue. [0007] The invention provides a topical composition [0005] Neutrophil infiltration results from amplifying comprising: cascades of cell-cell communication involving signal transduction proteins such as G-proteins that can facili- 40 at least one polyisoprenyl-protein inhibitor com- tate intracellular regulation and intercellular communica- pound, wherein the at least one polyisoprenyl-pro- tion by interactingwith a widerange of different regulatory tein inhibitor compound comprises a compound of receptor-transducer proteins such as membrane-bound Formula 1; receptors. For these interactions to occur, many of the signal transduction proteins, including virtually all G- pro- 45 teins, must first be modified by the post- translational ad- dition of a C 15 farnesyl or C20 geranylgeranyl polyiso- prenoid moiety in thioether linkage to a cysteine residue located at or near the carboxy terminus within a so- called or its pharmaceutically acceptable salts and esters CAAX box or related cysteine- containing sequence. Car- 50 thereof, wherein boxy terminal polyisoprenoid cysteines that ultimately re- R1 is alkyl of 1 to 3 carbon atoms; 2 sult from these modifications are subject to methylester- R is --COX; wherein X is --OH, --OCH3, --NH2, 4 4 ification by a specific membrane-associated S- adenosyl- --NHR , --N(R )2 or halogen; methionine-dependent polyisoprenyl-S-cysteinyl meth- R3 is a straight or branched chain alkyl of 10 to 25 yltransferase. Compounds that can inhibit these enzy- 55 carbon atoms or a straight or branched chain alkenyl matic reactions or otherwise alter the interactions among of 10 to 25 carbon atoms; and polyisoprenylated signal transduction proteins, such as R4 is an alkyl of 1 to 25 carbon atoms; and a carrier; G-proteins and the protein regulatory targets with which 2 3 EP 1 765 376 B1 4 wherein said topical composition is in the form of a pow- 10 to 25 carbon atoms; and R 4 is an alkyl of 1 to 25 carbon der, an oil, a cream, a gel, or a bandage, and wherein atoms; and the topicalcomposition is formulatedto deliveran amount wherein the topical composition is formulated to deliver of at least one polyisoprenyl-protein inhibitor compound an amount of the at least one polyisoprenyl-protein in- that is effective to inhibit inflammation when applied top- 5 hibitor compound that is effective to inhibit inflammation ically. when applied topically. [0008] In another embodiment, provided herein is a topical composition comprising at least one polyisopre- BRIEF DESCRIPTION OF THE FIGURES nyl-protein inhibitor compound selected from the group consisting of S-farnesylcysteine, N-acetyl-S-geranyl- 10 [0012] FIG 1. Induction of edema by TPA cysteine, N-acetyl-S-farnesylcysteine ("AFC"), also re- [0013] FIG 2. AFC, alone, does not cause mouse ear ferred to as N-acetyl-S-trans, trans-famesyl-L-cysteine, edema. N-acetyl-S-geranylgeranylcysteine ("AGGC"), far-S- [0014] FIG 3. AFC inhibits TPA-induced edema nesyl-2-mercaptoethanesulfonic acid, farnesylthio-S- [0015] FIG 4. AFC treatment produces a dose depend- acetic acid, S-farnesylmercaptosuccinic acid, S-far- 15 ent inhibition of TPA-induced MPO nesylthiotriazole, S-farnesylthiosalicylic acid ("FTS"), S- [0016] FIG 5. Histology of AFC inhibition of neutrophil farnesylthiosuccinic acid, 2-chloro-5-farnesylaminoben- infiltration zoic acid, 2-famesyl-thionicotinic acid ("FTN"), 5-fluoro- [0017] FIG 6. AFC inhibits TPA-induced neutrophil in- FTS, 5-chloro-FTS, 4-chloro-FTS, S-farnesyl-methylthi- filtration osalicylic acid and combinations thereof; and a carrier; 20 [0018] FIG 7. AFC inhibition of TPA-induced MPO ac- wherein said topical composition is in the form of a pow- tivity at different application times der, an oil, a cream, a gel, or a bandage, and wherein [0019] FIG 8A. AFC does not effect TPA-induced MPO the topicalcomposition is formulatedto deliveran amount activity in the contralateral vehicle treated ear. of at least one polyisoprenyl-protein inhibitor compound [0020] FIG 8B. Dexamethasone acts to increase inhi- that is effective to inhibit inflammation when applied top- 25 bition of TPA-induced MPO activity in the contralateral ically.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al
    USOO9636405B2 (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin et al. (45) Date of Patent: May 2, 2017 (54) FOAMABLE VEHICLE AND (56) References Cited PHARMACEUTICAL COMPOSITIONS U.S. PATENT DOCUMENTS THEREOF M (71) Applicant: Foamix Pharmaceuticals Ltd., 1,159,250 A 1 1/1915 Moulton Rehovot (IL) 1,666,684 A 4, 1928 Carstens 1924,972 A 8, 1933 Beckert (72) Inventors: Dov Tamarkin, Maccabim (IL); Doron 2,085,733. A T. 1937 Bird Friedman, Karmei Yosef (IL); Meir 33 A 1683 Sk Eini, Ness Ziona (IL); Alex Besonov, 2,586.287- 4 A 2/1952 AppersonO Rehovot (IL) 2,617,754. A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (73) Assignee: EMY PHARMACEUTICALs 2.968,628 A 1/1961 Reed ... Rehovot (IL) 3,004,894. A 10/1961 Johnson et al. (*) Notice: Subject to any disclaimer, the term of this 3,062,715. A 1 1/1962 Reese et al. tent is extended or adiusted under 35 3,067,784. A 12/1962 Gorman pa 3,092.255. A 6/1963 Hohman U.S.C. 154(b) by 37 days. 3,092,555 A 6/1963 Horn 3,141,821 A 7, 1964 Compeau (21) Appl. No.: 13/793,893 3,142,420 A 7/1964 Gawthrop (22) Filed: Mar. 11, 2013 3,144,386 A 8/1964 Brightenback O O 3,149,543 A 9/1964 Naab (65) Prior Publication Data 3,154,075 A 10, 1964 Weckesser US 2013/0189193 A1 Jul 25, 2013 3,178,352.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • United States Patent (19) 11 Patent Number: 4,780,463 Sunshine Et Al
    United States Patent (19) 11 Patent Number: 4,780,463 Sunshine et al. (45) Date of Patent: Oct. 25, 1988 (54). ANALGESIC, ANTI-INFLAMMATORY AND Ailments of the Musculoskeletal Apparatus), Investiga SKELETAL MUSCLE RELAXANT tion Medica Internactional, pp. 475-478, (1983), and COMPOSITIONS COMPRISING English translation thereof. NON-STEROIDAL ANTI-NFLAMMATORY Socialist Republic of Romania Description of Inven DRUGS AND MUSCULOSKELETAL tion, 82,717, copy of patent and English translation RELAXANTS AND METHODS OF USING thereof. SAME Rego, "Mio-Relaxantes No Tratamento Das Lom 75 Inventors: Abraham Sunshine, New York; balgias Aguda E Da Lombo-Ciaticas Recentes', Mus Eugene M. Laska, Larchmont; cle Relaxants in the Treatment of Acute Lumbalgias Carole E. Siegel, Mamaroneck, all of and Recent Lumbo-Sciatica Cases, Acta N.Y. Reumatologica Portuguesa, II, 2:363-364, (1974), copy of the original and English translation thereof. 73 Assignee: Analgesic Associates, Larchmont, Schror, "Analgetisch-antiphlogistische Therapie Von N.Y. Schmerzzustanden des Bewegungsapparates', Anal 21 Appl. No.: 114,751. gesic-Antiphlogistic Therapy of Locomotor System Pain), Therapiewoche, 28, 5657-5663, (1978), copy of the 22 Filed: Oct. 30, 1987 original and English translation thereof. Schar, "Medikamentose Behandling von Lumboishial Related U.S. Application Data gien', Drug Treatment of the Lumbago-Sciatic Syn 60 Division of Ser. No. 815,502, Jan. 2, 1986, Pat. No. drome, Schweiz. Rundschau Med., (Praxis), vol. 68, No. 4,722,938, which is a continuation of Ser. No. 686,380, 5, pp. 141-142, (Jan. 30, 1979), copy of original article Dec. 26, 1984, abandoned. and English translation thereof. 51) int. Cl.' ..................... A61K 31/19; A61K 31/44; Kolodny and Klipper, "Bone and Joint Diseases in the A61K 3/54; A61K 31/195; A61K 31/205 Elderly', Hospital Practice, pp.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Inflammatory Drug
    Abbreviations used: AR(s), adverse hepatotoxicity, 17 reaction(s); ADR(s), adverse drug manufacturers, 9 reaction(s); NSAID(s), non-steroid anti­ amorfazone, trade mark names and inflammatory drug(s) manufacturers, 9 Amuno, generic name and manufacturer, 12 anaemia absorption interactions, drug, 180-1 aplastic, 83 acemetacin, trade mark names and report rate, 33 manufacturers, 8 haemolytic, 84-5 acetyl salicylic acid, see Aspirin in rheumatoid patients, inappropriate action, drug, ~ pharmacoactivity therapy, 250 activation (of drugs), 243-5, 246, 247 anaphylaxis/anaphylactoid reactions, 17, pathway, 244 81 Actol, generic name and manufacturer, 13 Anaprox, generic name and manufacturer, Actosal, generic name and manufacturer, 13 9 angioedema, 6 acyl-coenzyme A formation, 221-2 angiotensin-converting enzyme, 195, 196 adjuvant induced arthritis, ~ inhibitors arthritis function, 195 Af1oxan, generic name and manufacturer, NSAID interactions with, 195-200 14 animal(s) age see also elderly experimentation, ethics of, 267 gastrointestinal susceptibility re­ inter species differences in lated to, 164, 286-8 propionate chiral inversion, use of anti-arthritics correlated 222-3, 223 with, 152 Ansaid, generic name and manufacturer, aged, the, ~ elderly 11 agranulocytosis antacids, 292 incidence, 7, 100-2 passim effect on drug absorption, 180, 181 in Sweden, 66, 67 NSAID interactions with, 185, 193 pyrazolone-induced, 7, 99-104 anthranilic acid, relative safety, 18 analytical epidemiological anti-arthritic drugs, ~ antirheumatic studies, 101-3 drugs
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,334,413 B2 Stock Et Al
    USOO8334413B2 (12) United States Patent (10) Patent No.: US 8,334,413 B2 Stock et al. (45) Date of Patent: Dec. 18, 2012 (54) TOPICAL COMPOSITIONS AND METHODS 5,837,224 A 11/1998 Voorhees et al. FOR EPITHELLAL-RELATED CONDITIONS 6,015,877 A 1/2000 Rando 6,096,740 A 8, 2000 Mechoulam et al. 6,114,388 A 9, 2000 Geffard (75) Inventors: Jeffry B. Stock, Princeton, NJ (US); 6,159,485 A 12/2000 Yu et al. Joel Gordon, Princeton Junction, NJ 6,251,882 B1 6/2001 Uckun et al. (US); Maxwell Stock, Rocky Hill, NJ 6,372,793 B1 4/2002 Lamango et al. 6,403,619 B1 6/2002 Jacobson et al. (US) 6,414,037 B1 7/2002 Pezzuto et al. 6,440,966 B1 8, 2002 Barrett et al. (73) Assignee: Signum Biosciences, Inc., Monmouth 6,462,086 B1 10/2002 Kloog et al. Junction, NJ (US) 6,482,086 B1 1 1/2002 Rimoto et al. 6,492,128 B1 12/2002 Haklai et al. (*) Notice: Subject to any disclaimer, the term of this 6,946,485 B2 9/2005 Kloog et al. patent is extended or adjusted under 35 7,365,080 B2 4/2008 Gregor et al. 7,576,094 B2 8, 2009 Chu et al. U.S.C. 154(b) by 0 days. 7,846,915 B2 12/2010 Wong et al. 2002/0010128 A1 1/2002 Parks et al. (21) Appl. No.: 12/968,800 2002/0182237 A1 12/2002 Bissett et al. 2003/005.9450 A1* 3/2003 Maibach et al.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
    WHO/EMP/RHT/TSN/2018.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization [2018] Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]
  • Novel Composition for Treating Metabolic Syndrome
    (19) & (11) EP 2 494 967 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 05.09.2012 Bulletin 2012/36 A61K 31/155 (2006.01) A61K 31/60 (2006.01) A61K 45/06 (2006.01) A61K 31/4045 (2006.01) (21) Application number: 12170283.1 (22) Date of filing: 16.01.2008 (84) Designated Contracting States: (72) Inventor: Chen, Chien-Hung AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Forest Hills, NY New York 11375 (US) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR (74) Representative: Coehn, Markus Fish & Richardson P.C. (30) Priority: 16.01.2007 US 885212 P Mies-van-der-Rohe-Strasse 8 80807 München (DE) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: Remarks: 08727718.2 / 2 118 279 This application was filed on 31-05-2012 as a divisional application to the application mentioned (71) Applicant: IPINTL, LLC under INID code 62. Flushing, NY 11354 (US) (54) Novel composition for treating metabolic syndrome (57) The invention relates to a composition that in- kinase (AMPK) activator; a second agent that possesses cludes a first agent selected from the group consisting anti-inflammatory activity; and a third agent that possess- of an oxidative phosphorylation inhibitor, an ionophore, es serotonin activity. and an adenosine 5’-monophosphate-activated Protein EP 2 494 967 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 494 967 A1 2 Description serotonin (e.g., serotonin sulfate, a serotonin creatinine sulfate complex, or serotonin hydrochloride) and a sero- CROSS-REFERENCE TO RELATED APPLICATION tonin re-uptake inhibitor.
    [Show full text]
  • Anti-Inflammatory/Analgesic Combination of Alpha
    Patentamt JEuropàischesEuropean Patent Office ® Publication number: 0 1 09 036 Office européen des brevets g "j © EUROPEAN PATENT SPECIFICATION (45) Dateof publication of patent spécification: 02.09.87 (jjj) jnt ci 4- A 61 K 31/415, A 61 K 31/62, (22) Dateoffiling: 08.11.83 (54) Anti-inf lammatory/analgesic combination of alpha-fluoromethylhistidine and a selected non-steroidal anti-inflammatory drug (NSAID). (§) Priority: 15.11.82 US 441581 (73) Proprietor: MERCK & CO. INC. 126, East Lincoln Avenue P.O. Box 2000 Rahway New Jersey 07065 (US) (43) Date of publication of application: 23.05.84 Bulletin 84/21 @ Inventor: Goldenberg, Marvin M. 721 Shackamaxon Drive (45) Publication of the grant of the patent: Westfield New Jersey 07090 (US) 02.09.87 Bulletin 87/36 (74) Representative: Abitz, Walter, Dr.-lng. et al (84) Designated Contracting States: Abitz, Morf, Gritschneder, Freiherr von CH DE FR GB IT LI NL Wittgenstein Postfach 86 01 09 D-8000 Munchen 86 (DE) (§) References cited: EP-A-0 046290 US-A-4325 961 CÛ (£> o o> o Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall CL be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been LU paid. (Art. 99( 1 ) European patent convention). Courier Press, Leamington Spa, England. BACKGROUND OF THE INVENTION This invention relates to novel pharmaceutical combinations comprising a-fluoromethylhistidine (FMH) and a non-steroidal anti-inflammatory/analgesic drug (NSAID) particularly indomethacin, diflunisal and naproxen.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]